What it sells
We use human data and AI to develop better drugs faster.
Business model breakdown
Buyer: who owns the budget?
UnverifiedR&D, translational and clinical development leaders at pharma and biotech.
Trigger: what makes them buy now?
Low clinical success rates; enriching a Parkinson's trial with vBx-1.0 lifts responders from 52% to 69%, cutting required enrollment 43%.
Workflow: what inputs become what output?
Platform used for target discovery, target characterization, biomarker identification and patient stratification; vBx foundation model produces a 'virtual biopsy' from a routine blood draw.
Economics: what it saves and how it charges
Pharma partnerships built on proprietary brain data and models; $1.6B in partnerships with top-20 pharma claimed.
Distribution: how it reaches customers
Business-development partnerships and platform access via Get in touch.
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| — | Y Combinator Summer 2015 | — | Y Combinator | ycombinator.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.